BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 25374844)

  • 1. Improved irritative voiding symptoms 3 years after stereotactic body radiation therapy for prostate cancer.
    Rana Z; Cyr RA; Chen LN; Kim BS; Moures RA; Yung TM; Lei S; Collins BT; Suy S; Dritschilo A; Lynch JH; Collins SP
    Front Oncol; 2014; 4():290. PubMed ID: 25374844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer.
    Arscott WT; Chen LN; Wilson N; Bhagat A; Kim JS; Moures RA; Yung TM; Lei S; Collins BT; Kowalczyk K; Suy S; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2014 Jul; 9():163. PubMed ID: 25056726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15).
    Aghdam N; Pepin A; Buchberger D; Hirshberg J; Lei S; Ayoob M; Danner M; Yung T; Kumar D; Collins BT; Lynch J; Kataria S; Suy S; Collins SP
    Front Oncol; 2020; 10():1060. PubMed ID: 32719744
    [No Abstract]   [Full Text] [Related]  

  • 4. Sexual, irritative, and voiding outcomes, following stereotactic body radiation therapy for prostate cancer.
    Rana Z; Hong RL; Abugideiri M; McRae D; Cernica G; Mordkin R; Joel AB; Bernstein G; Nasr NM
    Radiat Oncol; 2015 Aug; 10():182. PubMed ID: 26310244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer.
    Woo JA; Chen LN; Bhagat A; Oermann EK; Kim JS; Moures R; Yung T; Lei S; Collins BT; Kumar D; Suy S; Dritschilo A; Lynch JH; Collins SP
    Front Oncol; 2014; 4():122. PubMed ID: 24904833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction.
    Repka MC; Guleria S; Cyr RA; Yung TM; Koneru H; Chen LN; Lei S; Collins BT; Krishnan P; Suy S; Dritschilo A; Lynch J; Collins SP
    Front Oncol; 2016; 6():122. PubMed ID: 27242962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP).
    Pepin A; Aghdam N; Shah S; Kataria S; Tsou H; Datta S; Danner M; Ayoob M; Yung T; Lei S; Gurka M; Collins BT; Krishnan P; Suy S; Hankins R; Lynch JH; Collins SP
    Front Oncol; 2020; 10():555. PubMed ID: 32432033
    [No Abstract]   [Full Text] [Related]  

  • 8. Proctitis following stereotactic body radiation therapy for prostate cancer.
    Joh DY; Chen LN; Porter G; Bhagat A; Sood S; Kim JS; Moures R; Yung T; Lei S; Collins BT; Ju AW; Suy S; Carroll J; Lynch JH; Dritschilo A; Collins SP
    Radiat Oncol; 2014 Dec; 9():277. PubMed ID: 25497602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.
    Chen LN; Suy S; Uhm S; Oermann EK; Ju AW; Chen V; Hanscom HN; Laing S; Kim JS; Lei S; Batipps GP; Kowalczyk K; Bandi G; Pahira J; McGeagh KG; Collins BT; Krishnan P; Dawson NA; Taylor KL; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2013 Mar; 8():58. PubMed ID: 23497695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potency preservation following stereotactic body radiation therapy for prostate cancer.
    Obayomi-Davies O; Chen LN; Bhagat A; Wright HC; Uhm S; Kim JS; Yung TM; Lei S; Batipps GP; Pahira J; McGeagh KG; Collins BT; Kowalczyk K; Bandi G; Kumar D; Suy S; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2013 Nov; 8():256. PubMed ID: 24180317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Age on Patient-Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer.
    Pepin A; Pernia M; Danner MT; Ayoob M; Yung TM; Lei S; Collins BT; Simeng S; Aghdam N; Collins SP
    Cureus; 2021 Mar; 13(3):e13780. PubMed ID: 33842156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer.
    Onishi K; Tanaka N; Miyake M; Nakai Y; Anai S; Torimoto K; Yamaki K; Asakawa I; Hasegawa M; Fujii T; Konishi N; Fujimoto K
    Clin Transl Radiat Oncol; 2019 Jan; 14():51-58. PubMed ID: 30547097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer.
    Bhattasali O; Chen LN; Woo J; Park JW; Kim JS; Moures R; Yung T; Lei S; Collins BT; Kowalczyk K; Suy S; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2014 Feb; 9():52. PubMed ID: 24512837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience.
    Mercado C; Kress MA; Cyr RA; Chen LN; Yung TM; Bullock EG; Lei S; Collins BT; Satinsky AN; Harter KW; Suy S; Dritschilo A; Lynch JH; Collins SP
    Front Oncol; 2016; 6():114. PubMed ID: 27200300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proctitis 1 Week after Stereotactic Body Radiation Therapy for Prostate Cancer: Implications for Clinical Trial Design.
    Paydar I; Cyr RA; Yung TM; Lei S; Collins BT; Chen LN; Suy S; Dritschilo A; Lynch JH; Collins SP
    Front Oncol; 2016; 6():167. PubMed ID: 27489794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for lower urinary tract symptoms in elderly men. For the Prostate Study Group of the Austrian Society of Urology.
    Haidinger G; Temml C; Schatzl G; Brössner C; Roehlich M; Schmidbauer CP; Madersbacher S
    Eur Urol; 2000 Apr; 37(4):413-20. PubMed ID: 10765071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
    Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
    Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic Body Radiation Therapy for Prostate Cancer: What is the Appropriate Patient-Reported Outcome for Clinical Trial Design?
    Woo JA; Chen LN; Wang H; Cyr RA; Bhattasali O; Kim JS; Moures R; Yung TM; Lei S; Collins BT; Suy S; Dritschilo A; Lynch JH; Collins SP
    Front Oncol; 2015; 5():77. PubMed ID: 25874188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.